Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488938 | 1.00 | CYP3A4 (0.41) | CYP3A4ADORA3CHRM1TBXA2RPTGS1 | |
| SCHEMBL3488633 | 0.95 | CYP3A4 (0.41) | CYP3A4ADORA3CHRM1TBXA2RPTGS1 | |
| SCHEMBL3488632 | 0.95 | CYP3A4 (0.41) | CYP3A4ADORA3CHRM1TBXA2RPTGS1 | |
| SCHEMBL13473708 | 0.95 | CYP3A4 (0.41) | CYP3A4ADORA3CHRM1TBXA2RPTGS1 | |
| SCHEMBL13473743 | 0.95 | CYP3A4 (0.41) | CYP3A4ADORA3CHRM1TBXA2RPTGS1 | |
| SCHEMBL13474442 | 0.95 | CYP3A4 (0.41) | CYP3A4ADORA3CHRM1TBXA2RPTGS1 | |
| SCHEMBL13473721 | 0.93 | CYP3A4 (0.41) | CYP3A4 | |
| SCHEMBL3490374 | 0.93 | CYP3A4 (0.41) | CYP3A4 | |
| SCHEMBL3490372 | 0.93 | CYP3A4 (0.41) | CYP3A4 | |
| SCHEMBL13474420 | 0.93 | CYP3A4 (0.41) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676785-B2 | HCV protease inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-06-13 | — | — | US | disclosed |
| US-9676785-B2 | HCV protease inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-06-13 | — | — | US | disclosed |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-20150031106-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031106-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140323465-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2014-10-30 | — | — | US | disclosed |
| US-8778877-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778877-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130017991-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8293705-B2 | HCV protease inhibitors and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293705-B2 | HCV protease inhibitors and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293705-B2 | HCV protease inhibitors and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2011002808-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323465-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CYP3A4 275/4885ADORA3 3598/4885CHRM1 4865/4885 |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CYP3A4 275/4885ADORA3 3598/4885CHRM1 4865/4885 |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CYP3A4 275/4885ADORA3 3598/4885CHRM1 4865/4885 |
| US-20150031106-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CYP3A4 275/4885ADORA3 3598/4885CHRM1 4865/4885 |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CYP3A4 275/4885ADORA3 3598/4885CHRM1 4865/4885 |
| US-20130017991-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CYP3A4 275/4885ADORA3 3598/4885CHRM1 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.